Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
Key Points
-
Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock.
-
It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products.
-
The stock is trading at just 10 times its earnings.
» Read more about: Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? »